» Articles » PMID: 16437584

Biochemical and Pathological Characterization of Lrrk2

Overview
Journal Ann Neurol
Specialty Neurology
Date 2006 Jan 27
PMID 16437584
Citations 98
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Mutations in leucine-rich repeat kinase 2 (LRRK2) recently have been identified as the most common genetic cause of late-onset sporadic and familial Parkinson's disease (PD). The studies herein explore the biological and pathological properties of Lrrk2.

Methods: Genetic analysis was performed to identify autopsied patients with the most common Lrrk2 mutation (G2019S). Using an antibody specific to Lrrk2, the biochemical and immunocytochemical distribution of Lrrk2 was assessed.

Results: Three patients with the G2019S Lrrk2 mutation were identified. Two patients demonstrated classic PD with Lewy bodies, although concurrent pathological changes consistent with Alzheimer's disease were also present in one of these individuals. The third patient was characterized by parkinsonism without Lewy bodies but demonstrated dystrophic neurites in the substantia nigra intensely stained for Lrrk2. Lrrk2 accumulations were unique to this patient and Lrrk2 was not detected in other types of pathological inclusions. Biochemical analysis showed that Lrrk2 is predominantly a soluble approximately 250 kDa cytoplasmic protein expressed throughout the brain but also in many other organs.

Interpretation: The reasons for the selective predisposition of patients with mutations in LRRK2 to develop parkinsonism remains unclear, but Lrrk2 mutations may prime select neuronal populations to cellular insults that can lead to aberrant protein aggregation.

Citing Articles

Targets to Search for New Pharmacological Treatment in Idiopathic Parkinson's Disease According to the Single-Neuron Degeneration Model.

Huenchuguala S, Segura-Aguilar J Biomolecules. 2024; 14(6).

PMID: 38927076 PMC: 11201619. DOI: 10.3390/biom14060673.


How Parkinson's Disease-Linked LRRK2 Mutations Affect Different CNS Cell Types.

Bailey H, Cookson M J Parkinsons Dis. 2024; 14(7):1331-1352.

PMID: 38905056 PMC: 11492021. DOI: 10.3233/JPD-230432.


Mechanistic Evaluation of miRNAs and Their Targeted Genes in the Pathogenesis and Therapeutics of Parkinson's Disease.

Arora T, Sharma G, Prashar V, Singh R, Sharma A, Changotra H Mol Neurobiol. 2024; 62(1):91-108.

PMID: 38823001 DOI: 10.1007/s12035-024-04261-x.


Development and validation of an expanded antibody toolset that captures alpha-synuclein pathological diversity in Lewy body diseases.

Altay M, Kumar S, Burtscher J, Jagannath S, Strand C, Miki Y NPJ Parkinsons Dis. 2023; 9(1):161.

PMID: 38062007 PMC: 10703845. DOI: 10.1038/s41531-023-00604-y.


Parkinson's disease: From genetics to molecular dysfunction and targeted therapeutic approaches.

Huang Y, Wei J, Cooper A, Morris M Genes Dis. 2023; 10(3):786-798.

PMID: 37396535 PMC: 10308076. DOI: 10.1016/j.gendis.2021.12.015.